IRIS
MIGLINO, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.639
AS - Asia 573
SA - Sud America 78
NA - Nord America 38
AF - Africa 4
Totale 13.332
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 12.630
SG - Singapore 256
CN - Cina 157
VN - Vietnam 121
BR - Brasile 49
US - Stati Uniti d'America 22
AR - Argentina 18
HK - Hong Kong 13
MX - Messico 9
BD - Bangladesh 5
ID - Indonesia 5
RU - Federazione Russa 4
AE - Emirati Arabi Uniti 3
IQ - Iraq 3
UA - Ucraina 3
CO - Colombia 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
IR - Iran 2
PE - Perù 2
PY - Paraguay 2
TT - Trinidad e Tobago 2
VE - Venezuela 2
CI - Costa d'Avorio 1
CR - Costa Rica 1
DZ - Algeria 1
GT - Guatemala 1
IN - India 1
JP - Giappone 1
KW - Kuwait 1
LB - Libano 1
MA - Marocco 1
NI - Nicaragua 1
NL - Olanda 1
PS - Palestinian Territory 1
RS - Serbia 1
SA - Arabia Saudita 1
TR - Turchia 1
UY - Uruguay 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 13.332
Salva come PNG Salva come JPEG
Città #
Genova 6.720
Genoa 3.823
Rapallo 1.216
Vado Ligure 827
Singapore 94
Beijing 51
Ho Chi Minh City 46
Bordighera 31
Hanoi 28
Ashburn 14
Hong Kong 13
Tianjin 8
Biên Hòa 6
Mexico City 6
Ninh Bình 5
Bắc Ninh 4
Da Nang 4
Hải Dương 4
Abu Dhabi 3
Buenos Aires 3
Corrientes 3
Guangzhou 3
Milan 3
Perugia 3
Lấp Vò 2
Phủ Lý 2
Ternopil 2
Trieste 2
Vinh 2
Abidjan 1
Alcobaça 1
Algiers 1
Apucarana 1
Aracaju 1
Araruama 1
Arima 1
As Samawah 1
As Sālimīyah 1
Asunción 1
Atlanta 1
Baghdad 1
Barquisimeto 1
Barretos 1
Bauru 1
Belgrade 1
Belo Horizonte 1
Belogorodka 1
Belén de Escobar 1
Bento Gonçalves 1
Blumenau 1
Bogotá 1
Braço do Norte 1
Bắc Giang 1
Caicó 1
Campina Grande do Sul 1
Campo Mourão 1
Caruaru 1
Chapada Gaúcha 1
Chennai 1
Chiclayo 1
Cuautitlán Izcalli 1
Culiacán 1
Curitiba 1
Córdoba 1
Del Viso 1
Denpasar 1
Depok 1
Elk Grove Village 1
Exu 1
Guatemala City 1
Haikou 1
Haiphong 1
Hortolândia 1
Hurlingham 1
Huế 1
Iguape 1
Ijuí 1
Ipatinga 1
Istanbul 1
Itabaiana 1
Itamari 1
Itu 1
Izhevsk 1
Jequié 1
Jiutepec 1
Johannesburg 1
Khulna 1
Lambaré 1
Lorena 1
Los Angeles 1
Macapá 1
Maldonado 1
Managua 1
Maracaibo 1
Maringá 1
Marília 1
Medellín 1
Meknes 1
Milltown 1
Moscow 1
Totale 12.999
Salva come PNG Salva come JPEG
Nome #
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 219
A novel Bim-BH3-derived Bcl-X(L) inhibitor: Biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity 206
Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes 198
Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse 187
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis 187
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 186
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 185
A case of Cunninghamella bertholettiae rhino-cerebral infection in a leukaemic patient and review of recent published studies 180
Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission. 176
Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes 175
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 172
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia 170
Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. 170
Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma 169
Adult Advanced Chronic Lymphocytic Leukemia: Computational Analysis of Whole-Body CT Documents a Bone Structure Alteration 168
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives 168
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients 167
Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation 167
Doxorubicin effect on myocardial metabolism as a prerequisite for subsequent development of cardiac toxicity: A translational18F-FDG PET/CT observation 163
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 163
Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients. 163
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. 162
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. 160
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question". 157
First line therapy with Fludarabine combinations in 42 patients with either post-myelodysplastic syndrome or therapy related acute myeloid leukaemia. 156
Amifostine promotes hemopoietic progenitor cell mobilization in patients with myelodysplastic syndrome. 156
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 156
Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma 155
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients 155
Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. 153
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 152
Molecular analysis of clonality in plasma cell dyscrasias. 151
Chronic graft versus host disease as a weapon for treating chronic myelomonocytic leukemia 150
Thalidomide in agnogenic and secondary myelofibrosis 149
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 147
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 146
Molecular analysis of the bcr rearrangement in a case of Ph'-negative blastic crisis of Ph'-positive chronic myelogenous leukemia. 144
Combination of liposomal Daunorubicin, Fludarabine, and Cytarabine (FLAD) in patients with poor- risk acute leukemia. 143
First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease 142
Bound and unbound pyridine dinucleotides in normal and glucose-6-phosphate dehydrogenase-deficient erythrocytes. 142
An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline 140
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia 138
Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia 137
Clonal B lymphocytes lack bcr rearrangement in Ph-positive chronic myelogenous leukaemia. 137
Early chemotherapy intensification with escalated beacopp in patients with advanced-stage hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two abvd cycles: Long-term results of the GITIL/FIL HD 0607 trial 137
Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis. 136
Hepatosplenic T-cell lymphoma with aberrant expression of serum β-HCG: A case report 135
Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: A Possible Role for RANK/RANKL Pathway 133
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. 132
Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of flt3-itd in npm1 mutated aml, irrespectively of flt3-itd allelic Burden 131
Polyclonal pattern of X-inactivation in multiple myeloma. 130
Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas 130
An unusual reaction to alpha interferon in a case of non Hodgkin's lymphoma. 129
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia 128
Ras activation in myelodysplastic syndromes: clinical and molecular study of the chronic phase of the disease. 126
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. 126
Masked Philadelphia chromosome due to atypical BCR/ABL localization on the 9q34 band and duplication of the der(9) in a case of chronic myelogenous leukemia 126
Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death 126
Effects of TNF-α inhibitors upon the mechanisms of action of VEGF. 125
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 124
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: A feasible and effective salvage treatment for lymphoid malignancies 124
Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11 124
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis 122
Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression. 121
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. 121
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. 121
Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity. 119
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients. 116
Clonal analysis of hematologic malignancies using Mediterranean G6PD mosaicism. 114
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 112
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment 112
SIRT6 inhibition as a novel approach for treating Acute Myeloid Leukemia 111
Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin’s lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation 109
Impact of hematological malignancies in patients undergoing cardiac surgery 109
Epigenetic Regulation in Myelodysplastic Syndrome as A Consequence of A MicroRNA Dysregulation 108
A new glucose-6-phosphate dehydrogenase variant with congenital nonspherocytic hemolytic anemia (G6PD Genova). Biochemical characterization and mosaicism expression in the heterozygote. 105
Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes. 104
Chronic lymphocytic leukemia cells impair osteoblastogenesis and promote osteoclastogenesis: role of TNFα, IL-6 and IL-11 cytokines 104
FRONT-LINE TREATMENT OF PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA WITH IMATINIB AND INTERFERON-ALPHA: 5-YEAR OUTCOME. 102
Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia. 101
Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing and allogeneic bone marrow transplant 100
High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. 96
A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML 95
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status 94
Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ chronic myeloid leukemia patients treated with Imatinib mesylate. 92
Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa 91
Mobilization/transplantation of peripheral blood progenitor cells for aggressive non-Hodgkin's lymphoma with marrow involvement. 91
Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens. 91
Vdelta1 T lymhocites from B-CLL patients recognize ULPB3 expressed on leukemic B cells and up-regulated by trans-retinoic acid 88
GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly. 86
Cutaneous manifestations of hematologic malignancies the experience of an Italian dermatology department 86
Detection of minimal residual disease in B-lymphoproliferative disorders: a three step SSCP-PCR method. 82
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis 80
Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment? 76
Leucemia mieloide acuta Profilo genetico 76
GM-IVA, a short induction course for de novo acute myeloid leukemia, suitable for the elderly. 75
Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases. 70
Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis 69
Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features 69
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation 65
Totale 13.172
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.591
article - articoli 43.492
book - libri 0
conference - conferenze 372
curatela - curatele 0
other - altro 437
patent - brevetti 0
selected - selezionate 0
volume - volumi 290
Totale 89.182
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021513 0 0 0 0 0 62 42 72 77 96 61 103
2021/20221.206 34 77 87 140 48 85 74 249 67 111 54 180
2022/20231.456 133 122 34 167 246 246 4 102 210 26 146 20
2023/2024908 48 81 23 110 74 208 68 112 30 20 42 92
2024/20252.360 64 163 70 158 234 231 267 434 79 98 285 277
2025/20261.930 534 165 323 347 511 50 0 0 0 0 0 0
Totale 13.533